Browse News
Filter News
Found 722,637 articles
-
Following reports that Pfizer has declined study requests for Paxlovid, the company and NIH are said to be in conversation about potential studies assessing a longer treatment period of the antiviral.
-
Scientists in New Zealand have found that mRNA-based COVID-19 vaccines produce greater antibody levels compared to adenovirus vector-based ones across major COVID-19 variants.
-
Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have unlocked the mechanism that drives widespread inflammation in inflammatory diseases.
-
Axsome Therapeutics announced that it published the results of its Ascend Phase-II clinical trial of AXS-05 to treat Major Depressive Disorder in The American Journal of Psychiatry.
-
Pfizer apparently hasn't begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.
-
Flagship Pioneering announced the launch of Sonata Therapeutics. The fledgling company was created by combining two Flagship companies, Inzen Therapeutics and Cygnal Therapeutics.
-
Greece’s Health Minister Thanos Plevris announced plans to sue Novartis over what he alleges are illegal practices. In addition to demanding compensation, the country is implementing a three-point plan.
-
The American Society of Gene and Cell Therapy annual meeting continues to see companies showcasing promising therapeutics for multiple disease indications.
-
Industrializing Autologous Cell and Gene Therapy Manufacturing to Bring Quality Products to Patie...
5/18/2022
Orgenesis is developing a point-of-care manufacturing platform for cell and gene and other advanced therapies to make them more widely available and significantly more affordable. -
ShouTi believes many targets addressed by biologic and peptide therapeutics can be reached by innovative, rationally-designed, best-in-class small molecules that don’t need refrigeration or injection.
-
Virongy is expanding again and has committed to a $471,000 expansion with up to 70 new jobs.
-
Hengrui Pharma is seeking to make medicines more available and affordable worldwide with the launch of Luzsana that opens up access to treatment for hundreds of illnesses.
-
The current president, CEO and board member, Keith Kendall, is departing Aquestive. He will be replaced by Daniel Barber, its current chief operating officer.
-
Applied Molecular Transport (AMT) provided a strategy update on Wednesday. Part of the update includes reducing its workforce by about 40% and funneling resources into its lead program.
-
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
BioSpace surveyed thousands of industry professionals to get the most current, accurate salary statistics. Read on to find out the top-paying jobs in each sector.
-
Global Diagnostics Market is estimated to reach US$ 12,159.8 Mn by 2030: Astute Analytica
5/18/2022
The Global Asthma Diagnostics Market was valued at US$ 3,385.5 Mn in 2021 and is forecasted to reach US$ 5,857.7 Mn by 2030, registering a CAGR of 6.5% over the projection period.
-
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
5/18/2022
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1.
-
Single use Bioprocessing Market worth $20.8 billion by 2026 – Exclusive Report by MarketsandMarkets™
5/18/2022
The central idea behind using single-use bioprocessing technology in the bioprocess is to decrease the cost associated with complicated steps such as cleaning, sterilization, and maintenance of steel-based bioreactor systems.